<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36176206</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-1331</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>European journal of neurology</Title><ISOAbbreviation>Eur J Neurol</ISOAbbreviation></Journal><ArticleTitle>Reply to the Letter to the Editor in response to "Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis".</ArticleTitle><Pagination><StartPage>283</StartPage><EndPage>284</EndPage><MedlinePgn>283-284</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ene.15586</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Nilo</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0513-9517</Identifier><AffiliationInfo><Affiliation>Experimental Neuropathology Unit, Division of Neuroscience, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neurology Unit and Neurorehabilitation Unit, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quattrini</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Experimental Neuropathology Unit, Division of Neuroscience, Institute of Experimental Neurology (INSPE), San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D016420">Comment</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Neurol</MedlineTA><NlmUniqueID>9506311</NlmUniqueID><ISSNLinking>1351-5101</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Eur J Neurol. 2022 Jul;29(7):1930-1939</RefSource><PMID Version="1">35263489</PMID></CommentsCorrections><CommentsCorrections RefType="CommentOn"><RefSource>Eur J Neurol. 2023 Jan;30(1):285-286</RefSource><PMID Version="1">36214082</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>30</Day><Hour>1</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36176206</ArticleId><ArticleId IdType="doi">10.1111/ene.15586</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Falzone YM, Domi T, Mandelli A, et al. Integrated evaluation of a panel of neurochemical biomarkers to optimize diagnosis and prognosis in amyotrophic lateral sclerosis. Eur J Neurol. 2022;29(7):1930-1939. doi:10.1111/ene.15321</Citation></Reference><Reference><Citation>Verde F, Silani V, Otto M. Neurochemical biomarkers in amyotrophic lateral sclerosis. Curr Opin Neurol. 2019;32(5):747-757. doi:10.1097/WCO.0000000000000744</Citation></Reference><Reference><Citation>Riva N, Gentile F, Cerri F, et al. Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. Brain. 2022;145(1):276-284. doi:10.1093/brain/awab285</Citation></Reference><Reference><Citation>Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-based biomarker for ALS and FTLD. Mol Neurobiol. 2018;55(10):7789-7801. doi:10.1007/s12035-018-0947-6</Citation></Reference><Reference><Citation>Majumder V, Gregory JM, Barria MA, Green A, Pal S. TDP-43 as a potential biomarker for amyotrophic lateral sclerosis: a systematic review and meta-analysis. BMC Neurol. 2018;18(1):90. doi:10.1186/s12883-018-1091-7</Citation></Reference><Reference><Citation>Conti E, Sala G, Diamanti S, et al. Serum naturally occurring anti-TDP-43 auto-antibodies are increased in amyotrophic lateral sclerosis. Sci Rep. 2021;11(1):1978. doi:10.1038/s41598-021-81,599-5</Citation></Reference><Reference><Citation>Sferruzza G, Bosco L, Falzone YM, et al. Neurofilament light chain as a biological marker for amyotrophic lateral sclerosis: a meta-analysis study. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23(5-6):446-457. doi:10.1080/21678421.2021.2007952</Citation></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. Phase 1-2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. N Engl J Med. 2020;383(2):109-119. doi:10.1056/NEJMoa2003715</Citation></Reference><Reference><Citation>Sugimoto K, Hiwasa T, Shibuya K, et al. Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis. J Neuroimmunol. 2018;325:54-60. doi:10.1016/j.jneuroim.2018.09.013</Citation></Reference><Reference><Citation>Shepheard SR, Wuu J, Cardoso M, et al. Urinary p75 ECD: a prognostic, disease progression, and pharmacodynamic biomarker in ALS. Neurology. 2017;88(12):1137-1143. doi:10.1212/WNL.0000000000003741</Citation></Reference><Reference><Citation>Lunetta C, Lizio A, Gerardi F, et al. Urinary neopterin, a new marker of the neuroinflammatory status in amyotrophic lateral sclerosis. J Neurol. 2020;267(12):3609-3616. doi:10.1007/s00415-020-10047-7</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>